 Enveric Biosciences NASDAQ:ENVB said that two new molecules, EV104a and EV104b, have been created to treat osteoarthritis OA along with other pain conditions and that pre-clinical in vitro testing is now underway. The biotech recently licensed a platform technology from Diverse Biotech that has led to the successful synthesis of the two new chemical entity conjugates of cannabidiol CBD linked to nonsteroidal anti-inflammatory drug NSAID celecoxib. 